People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Biomimetic Therapeutics, Inc. | — | Biotechnology | Series A | $10.9M | $105.5M | 2009 |
| Lynch Regenerative Medicine, Llc | — | Other Health Care | Seed | $3.8M | $20.2M | 2024 |
SAMUEL LYNCH at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside SAMUEL LYNCH on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Chris Ehrlich | 1 | 6 |
| James Murphy | 1 | 5 |
| Larry Papasan | 1 | 3 |
| Steven Hirsch | 1 | 2 |
| Douglas Watson | 1 | 2 |
| Charles Federico | 1 | 2 |
| Larry Bullock | 1 | 1 |
| Russ Pagano | 1 | 1 |
| Thorkil Christensen | 1 | 1 |
| Earl Douglas | 1 | 1 |
| Gary Friedlaender | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.